These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 17200349

  • 21. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer.
    Nakayama N, Nakayama K, Shamima Y, Ishikawa M, Katagiri A, Iida K, Miyazaki K.
    Cancer; 2010 Jun 01; 116(11):2621-34. PubMed ID: 20336784
    [Abstract] [Full Text] [Related]

  • 22. Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel.
    Su D, Smith SM, Preti M, Schwartz P, Rutherford TJ, Menato G, Danese S, Ma S, Yu H, Katsaros D.
    Cancer; 2009 Jun 01; 115(11):2453-63. PubMed ID: 19322891
    [Abstract] [Full Text] [Related]

  • 23. Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients.
    Ferrandina G, Zannoni GF, Martinelli E, Paglia A, Gallotta V, Mozzetti S, Scambia G, Ferlini C.
    Clin Cancer Res; 2006 May 01; 12(9):2774-9. PubMed ID: 16675570
    [Abstract] [Full Text] [Related]

  • 24. Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study.
    Pignata S, Ferrandina G, Scarfone G, Scollo P, Odicino F, Cormio G, Katsaros D, Frigerio L, Mereu L, Ghezzi F, Manzione L, Lauria R, Breda E, Alletti DG, Ballardini M, Vernaglia A, Sorio R, Tumolo S, Musso P, Magni G, Pisano C, Morabito A.
    Crit Rev Oncol Hematol; 2009 Sep 01; 71(3):233-41. PubMed ID: 19179095
    [Abstract] [Full Text] [Related]

  • 25. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
    Yanagie H, Hisa T, Ogata A, Miyazaki A, Nonaka Y, Nishihira T, Osada I, Sairennji T, Sugiyama H, Furuya Y, Kidani Y, Takamoto S, Takahashi H, Eriguchi M.
    Biomed Pharmacother; 2009 Sep 01; 63(8):553-60. PubMed ID: 18571892
    [Abstract] [Full Text] [Related]

  • 26. Survival among patients with platinum resistant, locally advanced non-small cell lung cancer treated with platinum-based systemic therapy.
    d'Amato TA, Pettiford BL, Schuchert MJ, Parker R, Ricketts WA, Luketich JD, Landreneau RJ.
    Ann Surg Oncol; 2009 Oct 01; 16(10):2848-55. PubMed ID: 19609620
    [Abstract] [Full Text] [Related]

  • 27. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.
    Smith S, Su D, Rigault de la Longrais IA, Schwartz P, Puopolo M, Rutherford TJ, Mor G, Yu H, Katsaros D.
    J Clin Oncol; 2007 Nov 20; 25(33):5172-9. PubMed ID: 18024864
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer.
    Karam AK, Chiang JW, Fung E, Nossov V, Karlan BY.
    Gynecol Oncol; 2009 Aug 20; 114(2):246-52. PubMed ID: 19500821
    [Abstract] [Full Text] [Related]

  • 32. Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer.
    Scurr LL, Guminski AD, Chiew YE, Balleine RL, Sharma R, Lei Y, Pryor K, Wain GV, Brand A, Byth K, Kennedy C, Rizos H, Harnett PR, deFazio A.
    Clin Cancer Res; 2008 Nov 01; 14(21):6924-32. PubMed ID: 18980987
    [Abstract] [Full Text] [Related]

  • 33. E2F7 and E2F8 keep the E2F family in balance.
    Moon NS, Dyson N.
    Dev Cell; 2008 Jan 01; 14(1):1-3. PubMed ID: 18194644
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance.
    Connor JP, Felder M.
    Gynecol Oncol; 2008 Nov 01; 111(2):330-5. PubMed ID: 18723214
    [Abstract] [Full Text] [Related]

  • 36. The homeobox gene BARX2 can modulate cisplatin sensitivity in human epithelial ovarian cancer.
    Sellar GC, Watt KP, Li L, Nelkin BD, Rabiasz GJ, Porteous DJ, Smyth JF, Gabra H.
    Int J Oncol; 2002 Nov 01; 21(5):929-33. PubMed ID: 12370737
    [Abstract] [Full Text] [Related]

  • 37. Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome.
    Vuaroqueaux V, Urban P, Labuhn M, Delorenzi M, Wirapati P, Benz CC, Flury R, Dieterich H, Spyratos F, Eppenberger U, Eppenberger-Castori S.
    Breast Cancer Res; 2007 Nov 01; 9(3):R33. PubMed ID: 17535433
    [Abstract] [Full Text] [Related]

  • 38. IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer.
    Spentzos D, Cannistra SA, Grall F, Levine DA, Pillay K, Libermann TA, Mantzoros CS.
    Endocr Relat Cancer; 2007 Sep 01; 14(3):781-90. PubMed ID: 17914107
    [Abstract] [Full Text] [Related]

  • 39. Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients.
    Mezzanzanica D, Fabbi M, Bagnoli M, Staurengo S, Losa M, Balladore E, Alberti P, Lusa L, Ditto A, Ferrini S, Pierotti MA, Barbareschi M, Pilotti S, Canevari S.
    Clin Cancer Res; 2008 Mar 15; 14(6):1726-33. PubMed ID: 18347173
    [Abstract] [Full Text] [Related]

  • 40. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma.
    Cohen S, Mosig R, Moshier E, Pereira E, Rahaman J, Prasad-Hayes M, Halpert R, Billaud JN, Dottino P, Martignetti JA.
    Gynecol Oncol; 2014 Sep 15; 134(3):591-8. PubMed ID: 24995581
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.